CD274 and non-small cell lung carcinoma: Checkmate-816 is a randomized, open label phase III clinical study conducted in multiple centers to evaluate the efficacy of drug o combined with chemotherapy in the neoadjuvant stage of resectable non-small-cell lung cancer compared with chemotherapy alone, regardless of the tumor PD-L1 expression level.